0.3061
price down icon9.94%   -0.0338
after-market アフターアワーズ: .32 0.0139 +4.54%
loading
前日終値:
$0.3399
開ける:
$0.32
24時間の取引高:
2.53M
Relative Volume:
0.47
時価総額:
$38.15M
収益:
$36.86M
当期純損益:
$-171.67M
株価収益率:
-0.2041
EPS:
-1.5
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
-17.76%
1か月 パフォーマンス:
-36.23%
6か月 パフォーマンス:
-84.85%
1年 パフォーマンス:
-93.12%
1日の値動き範囲:
Value
$0.3061
$0.3324
1週間の範囲:
Value
$0.3061
$0.42
52週間の値動き範囲:
Value
$0.3061
$4.64

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name
名前
Mersana Therapeutics Inc
Name
セクター
Healthcare (1174)
Name
電話
617-498-0020
Name
住所
840 MEMORIAL DRIVE, CAMBRIDGE
Name
職員
0
Name
Twitter
@MersanaADC
Name
次回の収益日
2025-03-03
Name
最新のSEC提出書
Name
MRSN's Discussions on Twitter

MRSN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MRSN
Mersana Therapeutics Inc
0.3061 38.15M 36.86M -171.67M -171.05M -1.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-06 開始されました William Blair Outperform
2024-11-15 再開されました Citigroup Buy
2024-03-19 アップグレード JP Morgan Underweight → Neutral
2024-02-29 アップグレード BTIG Research Neutral → Buy
2024-02-29 アップグレード Guggenheim Neutral → Buy
2024-02-29 アップグレード Wedbush Neutral → Outperform
2023-12-04 アップグレード Citigroup Neutral → Buy
2023-07-28 ダウングレード Robert W. Baird Outperform → Neutral
2023-07-27 ダウングレード BTIG Research Buy → Neutral
2023-07-27 ダウングレード Citigroup Buy → Neutral
2023-07-27 ダウングレード Guggenheim Buy → Neutral
2023-07-27 ダウングレード JP Morgan Neutral → Underweight
2023-07-27 ダウングレード Truist Buy → Hold
2023-07-27 ダウングレード Wedbush Outperform → Neutral
2023-06-16 ダウングレード JP Morgan Overweight → Neutral
2023-06-15 開始されました Guggenheim Buy
2023-03-16 アップグレード JP Morgan Neutral → Overweight
2023-01-20 開始されました Citigroup Buy
2022-11-21 開始されました Truist Buy
2021-10-15 再開されました BTIG Research Buy
2021-08-30 開始されました H.C. Wainwright Buy
2021-03-31 開始されました Credit Suisse Neutral
2020-12-03 開始されました Stifel Buy
2020-09-29 再開されました JP Morgan Neutral
2020-04-29 開始されました BTIG Research Buy
2020-01-21 繰り返されました H.C. Wainwright Buy
2019-03-11 ダウングレード JP Morgan Neutral → Underweight
2018-11-14 アップグレード Leerink Partners Mkt Perform → Outperform
2018-05-08 開始されました Robert W. Baird Outperform
2018-03-19 ダウングレード JP Morgan Overweight → Neutral
すべてを表示

Mersana Therapeutics Inc (MRSN) 最新ニュース

pulisher
Apr 02, 2025

When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com

Apr 02, 2025
pulisher
Apr 01, 2025

Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan

Apr 01, 2025
pulisher
Mar 28, 2025

Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st

Mar 27, 2025
pulisher
Mar 20, 2025

MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India

Mar 20, 2025
pulisher
Mar 13, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 10, 2025

Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat

Mar 10, 2025
pulisher
Mar 08, 2025

Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St

Mar 08, 2025
pulisher
Mar 07, 2025

Mersana Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Brokers Issue Forecasts for MRSN Q1 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q1 EPS Estimate for Mersana Therapeutics Reduced by Analyst - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance

Mar 05, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics (NASDAQ:MRSN) Receives “Outperform” Rating from Wedbush - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics Reports Progress and Financial Results - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics’ Earnings Call Highlights Clinical Progress and Financial Gains - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics reports Q4 EPS (11c), consensus (17c) - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics Announces Positive Phase 1 Clinical Data - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Mersana's ADC Pipeline Advances: FDA Fast Track Designation as Q4 Losses Narrow - StockTitan

Mar 03, 2025
pulisher
Mar 02, 2025

What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings - GuruFocus.com

Mar 02, 2025
pulisher
Mar 01, 2025

MRSN stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com Australia

Mar 01, 2025
pulisher
Mar 01, 2025

William Blair starts Mersana stock with Outperform rating - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

Mersana Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Mersana Therapeutics faces Nasdaq delisting over share price - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

MRSN stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com - Investing.com South Africa

Feb 28, 2025

Mersana Therapeutics Inc (MRSN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
大文字化:     |  ボリューム (24 時間):